Biotechnology

In LUCENT-2, more than one in four (27.7%) Omvoh-treated patients with ulcerative colitis achieved comprehensive disease control, a…

Speaking during a webinar hosted by the International Alliance of Dietary and Food Supplement Associations (IADSA) last week,…

UnitedHealth Group signage on the floor of the New York Stock Exchange on April 21, 2025. Michael Nagle…

The mature dietary supplement market has been drawing increasing scrutiny from regulators, inspectors and legacy supplement brands. (Colorsandia…

RESEARCH HIGHLIGHT 05 October 2026 Glucagon-like peptide 1 (GLP-1) receptor agonists are approved for the treatment of type…

People who switched from obesity injections to Novo‘s new Wegovy pill continued to lose weight after three months,…

Small robots typically struggle on soft ground. Their motors may be strong enough to move their legs, although…

Startup entrepreneurs demonstrate an autonomous precision spraying drone for targeted pesticide application during the Krishi Mela at the…

Buck Institute aims to advance bioinformatics using Oracle Life Sciences Data Intelligence to transform aging research into a…

Guo, Q., Liang, J., Chang, T. & Cui, H.-L. Millimeter-wave imaging with accelerated super-resolution range migration algorithm. IEEE…

An Obamacare sign is displayed outside an insurance agency on Nov. 12, 2025, in Miami. Joe Raedle |…

Galimedix Therapeutics, Inc., a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the…

New composite outcomes data show patients treated with Lilly’s Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn’s disease at one year